SARS-CoV-2 S-Protein ACE2 Binding Domain Antibody
Product Specifications
Background
The novel SARS-coronavirus 2 (SARS-CoV-2) which causes the disease COVID-19 has been shown to utilize the SARS-CoV receptor ACE2 for entry into human cells (Hoffman, M. et al., Cell 2020) . The entry of a coronavirus into host cells is mediated by the viral surface-anchored transmembrane spike (S) glycoprotein which is composed of two functional subunits, S1 which binds the receptor and S2 which fuses the membrane (Walls, AC et.al., Cell 2020) . S1 contains a receptor-binding domain (RBD) which specifically recognizes ACE2 as its receptor (Wan, Y. et al., 2020) .
Swiss Prot
P0DTC2
Host
Mouse
Cross Reactivity
SARS-CoV-2
Target
SARS-CoV-2 S-Protein ACE2 Binding Domain
Clonality
Monoclonal
Isotype
IgG1
Clone
2G1
Conjugation
Unconjugated
Source
Recombinant SARS-CoV-2 S-Protein construct containing the ACE2 binding domain expressed in and purified from E. coli.
Applications
WB
Purification
Purified by Protein G.
Concentration
Lot Dependent
Dilution
WB (1:300-5000)
Buffer
PBS + 50% glycerol and 5 mm NaN3
Modification
Unmodified
Storage Conditions
Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C.
Specificity
Specific for the ~25 kDa ACE2 binding domain construct of SARS-CoV-2 S protein. Full-length CoV-2 S protein is ~142 kDa.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC470383-100 1x 100 µL
Cytokeratin 8 (K8/383), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
